1. Home
  2. XFOR vs AZI Comparison

XFOR vs AZI Comparison

Compare XFOR & AZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • AZI
  • Stock Information
  • Founded
  • XFOR 2014
  • AZI 2010
  • Country
  • XFOR United States
  • AZI China
  • Employees
  • XFOR N/A
  • AZI N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • AZI
  • Sector
  • XFOR Health Care
  • AZI
  • Exchange
  • XFOR Nasdaq
  • AZI Nasdaq
  • Market Cap
  • XFOR 118.4M
  • AZI 98.3M
  • IPO Year
  • XFOR N/A
  • AZI 2024
  • Fundamental
  • Price
  • XFOR $0.40
  • AZI $1.72
  • Analyst Decision
  • XFOR Strong Buy
  • AZI
  • Analyst Count
  • XFOR 4
  • AZI 0
  • Target Price
  • XFOR $2.88
  • AZI N/A
  • AVG Volume (30 Days)
  • XFOR 4.9M
  • AZI 1.7M
  • Earning Date
  • XFOR 11-13-2024
  • AZI 11-26-2024
  • Dividend Yield
  • XFOR N/A
  • AZI N/A
  • EPS Growth
  • XFOR N/A
  • AZI N/A
  • EPS
  • XFOR N/A
  • AZI N/A
  • Revenue
  • XFOR $1,123,000.00
  • AZI $117,732,000.00
  • Revenue This Year
  • XFOR N/A
  • AZI N/A
  • Revenue Next Year
  • XFOR $596.79
  • AZI N/A
  • P/E Ratio
  • XFOR N/A
  • AZI N/A
  • Revenue Growth
  • XFOR N/A
  • AZI 8.62
  • 52 Week Low
  • XFOR $0.26
  • AZI $0.75
  • 52 Week High
  • XFOR $1.60
  • AZI $4.05
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 39.99
  • AZI N/A
  • Support Level
  • XFOR $0.26
  • AZI N/A
  • Resistance Level
  • XFOR $0.68
  • AZI N/A
  • Average True Range (ATR)
  • XFOR 0.08
  • AZI 0.00
  • MACD
  • XFOR -0.01
  • AZI 0.00
  • Stochastic Oscillator
  • XFOR 34.01
  • AZI 0.00

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares

Autozi Internet Technology (Global) Ltd is one of China's leading and fast-growing lifecycle automotive service providers. It provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels nationwide. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.

Share on Social Networks: